Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study of Trametinib in Combination With Radioiodine (RAI) for RAS Mutant or RAS/RAF Wild-Type, RAI-Refractory Recurrent and/or Metastatic Thyroid Cancers

Next Previous
Trial Profile

A Phase 2 Study of Trametinib in Combination With Radioiodine (RAI) for RAS Mutant or RAS/RAF Wild-Type, RAI-Refractory Recurrent and/or Metastatic Thyroid Cancers

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Trametinib (Primary) ; Iodine-124; Iodine-131
  • Indications Carcinoma; Thyroid cancer
  • Focus Pharmacodynamics; Therapeutic Use

Most Recent Events

  • 24 Feb 2025 Planned End Date changed from 25 Jan 2025 to 25 Jan 2026.
  • 26 Jan 2024 Planned End Date changed from 12 Jan 2024 to 25 Jan 2025.
  • 03 Feb 2023 Planned End Date changed from 12 Jan 2023 to 12 Jan 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top